穀胱甘肽是生物體內一種相當重要的小分子硫醇，其能扮演抗氧化劑來調節細胞的氧化還原壓力之外，同時也參與多項的生理代謝反應。再者，由於大部分腫瘤組織中穀胱甘肽的濃度皆為正常組織的數倍，此濃度的差異對於治療癌症的奈米載體而言，被視為一個良好的引信訊號來促使藥物釋放。過去有許多以穀胱甘肽為引信的微脂體藥物陸續被開發，其中大多數的研究皆以利用具有還原應答能力的非天然性磷脂質來作為微脂體的主要脂質組成，但此種磷脂質可能造成生物相容性上的相關疑慮。在本研究中，我們利用自然界的膜活性胜肽為基礎，成功開發了以穀胱甘肽為引信的破膜胜肽，並且此狀態下的破膜活性會被胜肽序列上的遮蔽區塊抑制。由於此多肽有硫醇敏感設計，與傳統多肽與微脂體的硫醇與丁二醯亞胺反應不相容，因此需開發新的多肽與微脂體共軛聯結方式。透過張力促使的疊氮-炔烴的環加成反應，我們成功地將此胜肽修飾於微脂體的表面上，也成功地促使引信穀胱甘肽可以控制微脂體的藥物釋放。從多肽的還原測試實驗中，可以發現此引信響應的胜肽可對於穀胱甘肽具有引信響應的能力，並同時轉變成具有高破膜活性的多肽型式。在藥物釋放方面，引信響應的多肽微脂體與腫瘤濃度下的穀胱甘肽作用後，其會造成較高比例藥物阿黴素的釋放。最後，我們藉由分析胜肽的圓二色光譜，發現此胜肽在與引信作用後，會造成胜肽兩親媒性二級結構上的增加，進而影響微脂體的藥物釋放。

Reduced glutathione (GSH) is an important low-molecular-weight physiological thiol that can be serve as antioxidant for balancing the redox environment of cells and adjusts many significant biological metabolisms. Because of the concentration of glutathione in cancerous tissue is higher than normal level, it can be used as a good triggering signal for nanocarrier to release drug. As a result, a lot of liposomal drugs that can be triggered release by glutathione have been developed in the past decade. However, most liposomes mentioned above are composed of thiol-responsive “unnatural” phospholipids, which have potential safety issue. In this study, we intend to develop a GSH-responsive peptidyl liposome which is more biocompatible. The designed thio-responsive peptide is not compatible with conventional thiol-maleimide chemistry to conjugate onto liposome, and new cross-linking chemistry is needed. We successfully developed peptide-to-liposome conjugation by strain-promote azide-alkyne cycloaddition. We also successfully induce the reductive cleavage of the GSH-responsive peptide on liposome and trigger liposome release. Finally, through the circular dichroism analysis, we discovered the correlation between amphiphilic helicity of liposomal peptide and liposome release.

[1] Bangham, A. D.; Horne, R. W., "Negative Staining of Phospholipids and Their
Structural Modification by Surface-Active Agents as Observed in the Electron
Microscope." J Mol Biol, 8, 1964, 660-8.
[2] Bangham, A. D.; Standish, M. M.; Weissmann, G., "The action of steroids and
streptolysin S on the permeability of phospholipid structures to cations." J Mol
Biol, 13 (1), 1965, 253-9.
[3] Sessa, G.; Weissmann, G., "Incorporation of Lysozyme into Liposomes - a Model
for Structure-Linked Latency." J Biol Chem, 245 (13), 1970, 3295-3301.
[4] Lasic, D. D., "Novel applications of liposomes." Trends Biotechnol, 16 (7), 1998,
307-21.
[5] Johnson, S. M., "The effect of charge and cholesterol on the size and thickness of
sonicated phospholipid vesicles." Biochim Biophys Acta, 307 (1), 1973, 27-41.
[6] Juliano, R. L.; Stamp, D., "The effect of particle size and charge on the clearance
rates of liposomes and liposome encapsulated drugs." Biochem Biophys Res
Commun, 63 (3), 1975, 651-8.
[7] Grull, H.; Langereis, S., "Hyperthermia-triggered drug delivery from temperature-
sensitive liposomes using MRI-guided high intensity focused ultrasound." J
Control Release, 161 (2), 2012, 317-327.
[8] Monteiro, N.; Martins, A.; Reis, R. L.; Neves, N. M., "Liposomes in tissue
engineering and regenerative medicine." J R Soc Interface, 11 (101), 2014,
20140459.
[9] Taylor, K. M. G.; Taylor, G.; Kellaway, I. W.; Stevens, J., "Drug Entrapment and
Release from Multilamellar and Reverse-Phase Evaporation Liposomes." Int J
Pharm, 58 (1), 1990, 49-55.
[10] Briuglia, M. L.; Rotella, C.; McFarlane, A.; Lamprou, D. A., "Influence of
cholesterol on liposome stability and on in vitro drug release." Drug Deliv Transl
Res, 5 (3), 2015, 231-42.
[11] Milla, P.; Dosio, F.; Cattel, L., "PEGylation of proteins and liposomes: a powerful
and flexible strategy to improve the drug delivery." Curr Drug Metab, 13 (1), 2012,
105-19.
[12] Gregoriadis, G., "Drug entrapment in liposomes." FEBS Lett, 36 (3), 1973, 292-6.
[13] Barenholz, Y., "Doxil (R) - The first FDA-approved nano-drug: Lessons learned." J
Control Release, 160 (2), 2012, 117-134.
[14] Matsumura, Y.; Maeda, H., "A New Concept for Macromolecular Therapeutics in
Cancer-Chemotherapy - Mechanism of Tumoritropic Accumulation of Proteins and
the Antitumor Agent Smancs." Cancer Res, 46 (12), 1986, 6387-6392.
[15] Fang, J.; Nakamura, H.; Maeda, H., "The EPR effect: Unique features of tumor
blood vessels for drug delivery, factors involved, and limitations and augmentation
of the effect." Adv Drug Deliver Rev, 63 (3), 2011, 136-151.
[16] Torchilin, V., "Tumor delivery of macromolecular drugs based on the EPR effect."
Adv Drug Deliver Rev, 63 (3), 2011, 131-135.
[17] Gregoriadis, G.; Wills, E. J.; Swain, C. P.; Tavill, A. S., "Drug-carrier potential of
liposomes in cancer chemotherapy." Lancet, 1 (7870), 1974, 1313-6.
[18] Patel, N. R.; Pattni, B. S.; Abouzeid, A. H.; Torchilin, V. P., "Nanopreparations to
overcome multidrug resistance in cancer." Adv Drug Deliver Rev, 65 (13-14), 2013,
1748-1762.
[19] Franco, M. S.; Gomes, E. R.; Roque, M. C.; Oliveira, M. C., "Triggered Drug
Release From Liposomes: Exploiting the Outer and Inner Tumor Environment."
Front Oncol, 11, 2021, 623760.
[20] Wang, Y. F.; Kohane, D. S., "External triggering and triggered targeting strategies
for drug delivery." Nat Rev Mater, 2 (6), 2017, 1-14.
[21] Mo, R.; Gu, Z., "Tumor microenvironment and intracellular signal-activated
nanomaterials for anticancer drug delivery." Mater Today, 19 (5), 2016, 274-283.
[22] Zhao, Y.; Ren, W.; Zhong, T.; Zhang, S.; Huang, D.; Guo, Y.; Yao, X.;
Wang, C.; Zhang, W. Q.; Zhang, X.; Zhang, Q., "Tumor-specific pH-responsive
peptide-modified pH-sensitive liposomes containing doxorubicin for enhancing
glioma targeting and anti-tumor activity." J Control Release, 222, 2016, 56-66.
[23] Zhang, S. Y.; Zhao, Y., "Controlled Release from Cleavable Polymerized Liposomes
upon Redox and pH Stimulation." Bioconjugate Chem, 22 (4), 2011, 523-528.
[24] Loew, M.; Forsythe, J. C.; McCarley, R. L., "Lipid Nature and Their Influence on
Opening of Redox-Active Liposomes." Langmuir, 29 (22), 2013, 6615-6623.
[25] Mizukami, S.; Kashibe, M.; Matsumoto, K.; Hori, Y.; Kikuchi, K., "Enzyme-
triggered compound release using functionalized antimicrobial peptide derivatives."
Chemical Science, 8 (4), 2017, 3047-3053.
[26] Sarkar, N.; Banerjee, J.; Hanson, A. J.; Elegbede, A. I.; Rosendahl, T.;
Krueger, A. B.; Banerjee, A. L.; Tobwala, S.; Wang, R. Y.; Lu, X. N.; Mallik,
S.; Srivastava, D. K., "Matrix metalloproteinase-assisted triggered release of
liposomal contents." Bioconjugate Chem, 19 (1), 2008, 57-64.
[27] Pourhassan, H.; Clergeaud, G.; Hansen, A. E.; Ostrem, R. G.; Fliedner, F. P.; Melander, F.; Nielsen, O. L.; O'Sullivan, C. K.; Kjaer, A.; Andresen, T. L., "Revisiting the use of sPLA(2)-sensitive liposomes in cancer therapy." J Control Release, 261, 2017, 163-173.
[28] Ong, W.; Yang, Y.; Cruciano, A. C.; McCarley, R. L., "Redox-triggered contents
release from liposomes." J Am Chem Soc, 130 (44), 2008, 14739-44.
[29] Van Laer, K.; Hamilton, C. J.; Messens, J., "Low-molecular-weight thiols in thiol-
disulfide exchange." Antioxid Redox Signal, 18 (13), 2013, 1642-53.
[30] Wu, G.; Fang, Y. Z.; Yang, S.; Lupton, J. R.; Turner, N. D., "Glutathione
metabolism and its implications for health." J Nutr, 134 (3), 2004, 489-92.
[31] Owen, J. B.; Butterfield, D. A., "Measurement of oxidized/reduced glutathione
ratio." Methods Mol Biol, 648, 2010, 269-77.
[32] Bounous, G.; Batist, G.; Gold, P., "Immunoenhancing property of dietary whey
protein in mice: role of glutathione." Clin Invest Med, 12 (3), 1989, 154-61.
[33] Droge, W.; Schulze-Osthoff, K.; Mihm, S.; Galter, D.; Schenk, H.; Eck, H. P.;
Roth, S.; Gmunder, H., "Functions of glutathione and glutathione disulfide in
immunology and immunopathology." FASEB J, 8 (14), 1994, 1131-8.
[34] Delaunay-Moisan, A.; Ponsero, A.; Toledano, M. B., "Reexamining the Function
of Glutathione in Oxidative Protein Folding and Secretion." Antioxid Redox Signal,
27 (15), 2017, 1178-1199.
[35] Deponte, M., "The Incomplete Glutathione Puzzle: Just Guessing at Numbers and
Figures?" Antioxid Redox Signal, 27 (15), 2017, 1130-1161.
[36] Ottaviano, F. G.; Handy, D. E.; Loscalzo, J., "Redox regulation in the extracellular
environment." Circ J, 72 (1), 2008, 1-16.
[37] Forman, H. J.; Zhang, H.; Rinna, A., "Glutathione: overview of its protective roles,
measurement, and biosynthesis." Mol Aspects Med, 30 (1-2), 2009, 1-12.
[38] Bachhawat, A. K.; Kaur, A., "Glutathione Degradation." Antioxid Redox Signal, 27
(15), 2017, 1200-1216.
[39] Franco, R.; Cidlowski, J. A., "Apoptosis and glutathione: beyond an antioxidant."
Cell Death Differ, 16 (10), 2009, 1303-14.
[40] Circu, M. L.; Aw, T. Y., "Glutathione and modulation of cell apoptosis." Biochim
Biophys Acta, 1823 (10), 2012, 1767-77.
[41] Townsend, D. M.; Tew, K. D.; Tapiero, H., "The importance of glutathione in
human disease." Biomed Pharmacother, 57 (3-4), 2003, 145-55.
[42] Sian, J.; Dexter, D. T.; Lees, A. J.; Daniel, S.; Agid, Y.; Javoy-Agid, F.;
Jenner, P.; Marsden, C. D., "Alterations in glutathione levels in Parkinson's disease
and other neurodegenerative disorders affecting basal ganglia." Ann Neurol, 36 (3),
1994, 348-55.
[43] Schulz, J. B.; Lindenau, J.; Seyfried, J.; Dichgans, J., "Glutathione, oxidative
stress and neurodegeneration." Eur J Biochem, 267 (16), 2000, 4904-11.
[44] Kameoka, M.; Okada, Y.; Tobiume, M.; Kimura, T.; Ikuta, K., "Intracellular
glutathione as a possible direct blocker of HIV type 1 reverse transcription." Aids
Res Hum Retrov, 12 (17), 1996, 1635-1638.
[45] Kelly, F. J., "Gluthathione: in defence of the lung." Food Chem Toxicol, 37 (9-10),
1999, 963-6.
[46] Biswas, S. K.; Rahman, I., "Environmental toxicity, redox signaling and lung
inflammation: the role of glutathione." Mol Aspects Med, 30 (1-2), 2009, 60-76.
[47] Yuan, L.; Kaplowitz, N., "Glutathione in liver diseases and hepatotoxicity." Mol
Aspects Med, 30 (1-2), 2009, 29-41.
[48] Schafer, F. Q.; Buettner, G. R., "Redox environment of the cell as viewed through
the redox state of the glutathione disulfide/glutathione couple." Free Radical Bio Med, 30 (11), 2001, 1191-1212.
[49] Jones, D. P., "Redox potential of GSH/GSSG couple: assay and biological
significance." Methods Enzymol, 348, 2002, 93-112.
[50] Adams, J. D.; Wang, B.; Klaidman, L. K.; Lebel, C. P.; Odunze, I. N.; Shah,
D., "New Aspects of Brain Oxidative Stress-Induced by Tert-Butylhydroperoxide."
Free Radical Bio Med, 15 (2), 1993, 195-202.
[51] Lovell, M. A.; Ehmann, W. D.; Butler, S. M.; Markesbery, W. R., "Elevated
thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain
in Alzheimer's disease." Neurology, 45 (8), 1995, 1594-601.
[52] Sofic, E.; Lange, K. W.; Jellinger, K.; Riederer, P., "Reduced and oxidized
glutathione in the substantia nigra of patients with Parkinson's disease." Neurosci
Lett, 142 (2), 1992, 128-30.
[53] Miller, V. M.; Lawrence, D. A.; Mondal, T. K.; Seegal, R. F., "Reduced
glutathione is highly expressed in white matter and neurons in the unperturbed
mouse brain--implications for oxidative stress associated with neurodegeneration."
Brain Res, 1276, 2009, 22-30.
[54] Lei, Y. L.; Huang, K.; Gao, C.; Lau, Q. C.; Pan, H.; Xie, K.; Li, J. Y.; Liu,
R.; Zhang, T.; Xie, N.; Nai, H. S.; Wu, H.; Dong, Q.; Zhao, X.; Nice, E. C.;
Huang, C. H.; Wei, Y. Q., "Proteomics Identification of ITGB3 as a Key Regulator
in Reactive Oxygen Species-induced Migration and Invasion of Colorectal Cancer
Cells." Mol Cell Proteomics, 10 (10), 2011.
[55] Patel, B. P.; Rawal, U. M.; Dave, T. K.; Rawal, R. M.; Shukla, S. N.; Shah, P.
M.; Patel, P. S., "Lipid peroxidation, total antioxidant status, and total thiol levels
predict overall survival in patients with oral squamous cell carcinoma." Integr
Cancer Ther, 6 (4), 2007, 365-372.
[56] Chaiswing, L.; Oberley, T. D., "Extracellular/microenvironmental redox state."
Antioxid Redox Signal, 13 (4), 2010, 449-65.
[57] Kuppusamy, P.; Li, H.; Ilangovan, G.; Cardounel, A. J.; Zweier, J. L.;
Yamada, K.; Krishna, M. C.; Mitchell, J. B., "Noninvasive imaging of tumor redox
status and its modification by tissue glutathione levels." Cancer Res, 62 (1), 2002,
307-12.
[58] Perry, R. R.; Mazetta, J. A.; Levin, M.; Barranco, S. C., "Glutathione levels and
variability in breast tumors and normal tissue." Cancer, 72 (3), 1993, 783-7.
[59] Russo, A.; DeGraff, W.; Friedman, N.; Mitchell, J. B., "Selective modulation of
glutathione levels in human normal versus tumor cells and subsequent differential
response to chemotherapy drugs." Cancer Res, 46 (6), 1986, 2845-8.
[60] Wu, C.; Gong, M. Q.; Liu, B. Y.; Zhuo, R. X.; Cheng, S. X., "Co-delivery of
multiple drug resistance inhibitors by polymer/inorganic hybrid nanoparticles to
effectively reverse cancer drug resistance." Colloid Surface B, 149, 2017, 250-259.
[61] Gamcsik, M. P.; Kasibhatla, M. S.; Teeter, S. D.; Colvin, O. M., "Glutathione
levels in human tumors." Biomarkers, 17 (8), 2012, 671-91.
[62] He, Q.; Chen, J.; Yan, J.; Cai, S.; Xiong, H.; Liu, Y.; Peng, D.; Mo, M.; Liu,
Z., "Tumor microenvironment responsive drug delivery systems." Asian J Pharm
Sci, 15 (4), 2020, 416-448.
[63] Guo, X. S.; Cheng, Y.; Zhao, X. T.; Luo, Y. L.; Chen, J. J.; Yuan, W. E.,
"Advances in redox-responsive drug delivery systems of tumor microenvironment."
J Nanobiotechnol, 16, 2018.
[64] Mollazadeh, S.; Mackiewicz, M.; Yazdimamaghani, M., "Recent advances in the
redox-responsive drug delivery nanoplatforms: A chemical structure and physical
property perspective." Mat Sci Eng C-Mater, 118, 2021, 11536.
[65] Wang, Z.; Ling, L. B.; Du, Y. W.; Yao, C.; Li, X. S., "Reduction responsive
liposomes based on paclitaxel-ss-lysophospholipid with high drug loading for
intracellular delivery." Int J Pharm, 564, 2019, 244-255.
[66] Chen, Y. F.; Hsu, M. W.; Su, Y. C.; Chang, H. M.; Chang, C. H.; Jan, J. S.,
"Naturally derived DNA nanogels as pH- and glutathione-triggered anticancer drug
carriers." Mat Sci Eng C-Mater, 114, 2020, 111025.
[67] Du, X.; Kleitz, F.; Li, X. Y.; Huang, H. W.; Zhang, X. J.; Qiao, S. Z.,
"Disulfide-Bridged Organosilica Frameworks: Designed, Synthesis, Redox-
Triggered Biodegradation, and Nanobiomedical Applications." Adv Funct Mater, 28
(26), 2018, 1707325.
[68] Cheng, Y.; Ji, Y. H., "Mitochondria-targeting nanomedicine self-assembled from
GSH-responsive paclitaxel-ss-berberine conjugate for synergetic cancer treatment
with enhanced cytotoxicity." J Control Release, 318, 2020, 38-49.
[69] Du, Y. W.; He, W.; Zhou, W. Y.; Li, X. S., "Disulfide phosphatidylcholines:
alternative phospholipids for the preparation of functional liposomes." Chem
Commun, 55 (58), 2019, 8434-8437.
[70] Nie, Y. Y.; Xu, Y. R.; Gao, Y.; He, J. L.; Sun, L.; Chen, J. M.; Cui, Y. S.; Ge,
H. X.; Ning, X. H., "A glutathione-triggered precision explosive system for
improving tumor chemosensitivity." Nano Res, 2020.
[71] Liu, D. C.; Chen, B. L.; Mo, Y. L.; Wang, Z. H.; Qi, T.; Zhang, Q.; Wang, Y.
G., "Redox-Activated Porphyrin-Based Liposome Remote-Loaded with
Indoleamine 2,3-Dioxygenase (IDO) Inhibitor for Synergistic Photoimmunotherapy
through Induction of Immunogenic Cell Death and Blockage of IDO Pathway (vol
19, pg 6964, 2019)." Nano Lett, 20 (2), 2020, 1476-1476.
[72] Elzes, M. R.; Akeroyd, N.; Engbersen, J. F. J.; Paulusse, J. M. J., "Disulfide-
functional poly(amido amine)s with tunable degradability for gene delivery." J
Control Release, 244, 2016, 357-365.
[73] Li, S. L.; Saw, P. E.; Lin, C. H.; Nie, Y.; Tao, W.; Farokhzad, O. C.; Zhang,
L.; Xu, X. D., "Redox-responsive polyprodrug nanoparticles for targeted siRNA
delivery and synergistic liver cancer therapy." Biomaterials, 234, 2020, 119760.
[74] Wang, B.; Zhang, J.; Liu, Y. H.; Zhang, W.; Xiao, Y. P.; Zhao, R. M.; Yu, X.
Q., "A reduction-responsive liposomal nanocarrier with self-reporting ability for
efficient gene delivery." J Mater Chem B, 6 (18), 2018, 2860-2868.
[75] Lv, H. Y.; Ma, S.; Wang, Z. B.; Ji, X. T.; Lv, S. P.; Ding, C. F., "Glutathione-
triggered non-template synthesized porous carbon nanospheres serve as low toxicity
targeted delivery system for cancer multi-therapy." Chinese Chem Lett, 32 (5), 2021,
1765-1769.
[76] Baldwin, A. D.; Kiick, K. L., "Reversible maleimide-thiol adducts yield glutathione-
sensitive poly(ethylene glycol)-heparin hydrogels." Polym Chem-Uk, 4 (1), 2013,
133-143.
[77] Cheng, G.; He, Y. Y.; Xie, L.; Nie, Y.; He, B.; Zhang, Z. R.; Gu, Z. W.,
"Development of a reduction-sensitive diselenide-conjugated oligoethylenimine
nanoparticulate system as a gene carrier." Int J Nanomed, 7, 2012, 3991-4006.
[78] Liang, Y. K.; Kiick, K. L., "Liposome-Cross-Linked Hybrid Hydrogels for
Glutathione-Triggered Delivery of Multiple Cargo Molecules." Biomacromolecules,
17 (2), 2016, 601-614.
[79] Zhai, S.; Hu, X.; Hu, Y.; Wu, B.; Xing, D., "Visible light-induced crosslinking
and physiological stabilization of diselenide-rich nanoparticles for redox-responsive
drug release and combination chemotherapy." Biomaterials, 121, 2017, 41-54.
[80] Galdiero, S.; Falanga, A.; Cantisani, M.; Vitiello, M.; Morelli, G.; Galdiero,
M., "Peptide-lipid interactions: experiments and applications." Int J Mol Sci, 14 (9),
2013, 18758-89.
[81] Jiang, Y. J.; Chen, Y. Y.; Song, Z. Y.; Tan, Z. Z.; Cheng, J. J., "Recent advances
in design of antimicrobial peptides and polypeptides toward clinical translation."
Adv Drug Deliver Rev, 170, 2021, 261-280.
[82] McMillan, K. A. M.; Coombs, M. R. P., "Review: Examining the Natural Role of
Amphibian Antimicrobial Peptide Magainin." Molecules, 25 (22), 2020, 5436.
[83] Li, Q. Q.; Chen, P. G.; Hu, Z. W.; Cao, Y.; Chen, L. X.; Chen, Y. X.; Zhao,
Y. F.; Li, Y. M., "Selective inhibition of cancer cells by enzyme-induced gain of
function of phosphorylated melittin analogues." Chem Sci, 8 (11), 2017, 7675-7681.
[84] Jiang, Z. Q.; Vasil, A. I.; Hale, J. D.; Hancock, R. E. W.; Vasil, M. L.; Hodges, R. S., "Effects of net charge and the number of positively charged residues on the biological activity of amphipathic alpha-helical cationic antimicrobial peptides." Biopolymers, 90 (3), 2008, 369-383.
[85] Li, M. Y.; Wang, S. J.; Xu, J.; Xu, S. H.; Liu, H. L., "pH/Redox-Controlled
Interaction between Lipid Membranes and Peptide Derivatives with a "Helmet"." J
Phys Chem B, 123 (31), 2019, 6784-6791.
[86] Mizukami, S.; Hosoda, M.; Satake, T.; Okada, S.; Hori, Y.; Furuta, T.;
Kikuchi, K., "Photocontrolled Compound Release System Using Caged
Antimicrobial Peptide." Journal of the American Chemical Society, 132 (28), 2010,
9524-9525.
[87] Mizukami, S.; Kashibe, M.; Matsumoto, K.; Hori, Y.; Kikuchi, K., "Enzyme-
triggered compound release using functionalized antimicrobial peptide derivatives
(vol 8, pg 3047, 2017)." Chemical Science, 8 (4), 2017, 3276-3276.
[88] Huang, J. R.; Lee, M. H.; Li, W. S.; Wu, H. C., "Liposomal Irinotecan for
Treatment of Colorectal Cancer in a Preclinical Model." Cancers, 11 (3), 2019.
[89] Yang, J.; Bahreman, A.; Daudey, G.; Bussmann, J.; Olsthoorn, R. C. L.; Kros,
A., "Drug Delivery via Cell Membrane Fusion Using Lipopeptide Modified
Liposomes." Acs Central Sci, 2 (9), 2016, 621-630.
[90] Zalipsky, S.; Mullah, N.; Harding, J. A.; Gittelman, J.; Guo, L.; DeFrees, S. A.,
"Poly(ethylene glycol)-grafted liposomes with oligopeptide or oligosaccharide
ligands appended to the termini of the polymer chains." Bioconjugate Chem, 8 (2),
1997, 111-118.
[91] Versluis, F.; Voskuhl, J.; van Kolck, B.; Zope, H.; Bremmer, M.; Albregtse,
T.; Kros, A., "In Situ Modification of Plain Liposomes with Lipidated Coiled Coil
Forming Peptides Induces Membrane Fusion." Journal of the American Chemical
Society, 135 (21), 2013, 8057-8062.
[92] Marques-Gallego, P.; de Kroon, A. I. P. M., "Ligation Strategies for Targeting
Liposomal Nanocarriers." Biomed Res Int, 2014, 2014, 1-12.
[93] Lim, S. K.; Sanden, C.; Selegard, R.; Liedberg, B.; Aili, D., "Tuning Liposome
Membrane Permeability by Competitive Peptide Dimerization and Partitioning-
Folding Interactions Regulated by Proteolytic Activity." Sci Rep-Uk, 6, 2016.
[94] Cavalli, S.; Overhand, M.; Kros, A., "Assembly into beta-Sheet Structures upon
Peptide-Liposome Conjugation through Copper(I)-Catalyzed [3+2] Azide-Alkyne
Cycloaddition." Chempluschem, 79 (4), 2014, 564-568.
[95] Ringhieri, P.; Mannucci, S.; Conti, G.; Nicolato, E.; Fracasso, G.; Marzola, P.;
Morelli, G.; Accardo, A., "Liposomes derivatized with multimeric copies of
KCCYSL peptide as targeting agents for HER-2-overexpressing tumor cells." Int J
Nanomed, 12, 2017, 501-514.
[96] Tarallo, R.; Accardo, A.; Falanga, A.; Guarnieri, D.; Vitiello, G.; Netti, P.;
D'Errico, G.; Morelli, G.; Galdiero, S., "Clickable Functionalization of Liposomes
with the gH625 Peptide from Herpes simplex Virus Type I for Intracellular Drug
Delivery." Chem-Eur J, 17 (45), 2011, 12659-12668.
[97] Bak, M.; Jolck, R. I.; Eliasen, R.; Andresen, T. L., "Affinity Induced Surface Functionalization of Liposomes Using Cu-Free Click Chemistry." Bioconjugate Chem, 27 (7), 2016, 1673-1680.
[98] Bernhard, Y.; Gigot, E.; Goncalves, V.; Moreau, M.; Sok, N.; Richard, P.;
Decreau, R. A., "Direct subphthalocyanine conjugation to bombesin vs. indirect
conjugation to its lipidic nanocarrier." Org Biomol Chem, 14 (19), 2016, 4511-4518.
[99] Blenke, E. O.; Klaasse, G.; Merten, H.; Pluckthun, A.; Mastrobattista, E.,
"Liposome functionalization with copper-free "click chemistry"." J Control Release,
202, 2015, 14-20.
[100] Goto, C.; Hirano, M.; Hayashi, K.; Kikuchi, Y.; Hara-Kudo, Y.; Misawa,
T.; Demizu, Y., "Development of Amphipathic Antimicrobial Peptide Foldamers
Based on Magainin 2 Sequence." ChemMedChem, 14 (22), 2019, 1911-1916.
[101] Dai, Y. X.; Yue, N.; Liu, C. X.; Cai, X. G.; Su, X.; Bi, X. Z.; Li, Q. F.;
Li, C. Y.; Huang, W. L.; Qian, H., "Synthesis and evaluation of redox-sensitive
gonadotropin-releasing hormone receptor-targeting peptide conjugates." Bioorg
Chem, 88, 2019, 102945.
[102] Klein, P. M.; Reinhard, S.; Lee, D. J.; Muller, K.; Ponader, D.;
Hartmann, L.; Wagner, E., "Precise redox-sensitive cleavage sites for improved
bioactivity of siRNA lipopolyplexes." Nanoscale, 8 (42), 2016, 18098-18104.
[103] Goddard-Borger, E. D.; Stick, R. V., "An efficient, inexpensive, and shelf-stable
diazotransfer reagent: imidazole-1-sulfonyl azide hydrochloride." Org Lett, 9 (19),
2007, 3797-800.
[104] Marine, J. E.; Liang, X.; Song, S.; Rudick, J. G., "Azide-rich peptides via an
on-resin diazotransfer reaction." Biopolymers, 104 (4), 2015, 419-26.
[105] Hansen, M. B.; van Gurp, T. H. M.; van Hest, J. C. M.; Lowik, D. W. P. M.,
"Simple and Efficient Solid-Phase Preparation of Azido-peptides." Organic Letters,
14 (9), 2012, 2330-2333.
[106] Castro, V.; Banco-Canosa, J. B.; Rodriguez, H.; Albericio, F., "Imidazole-1-
sulfonyl Azide-Based Diazo-Transfer Reaction for the Preparation of Azido Solid
Supports for Solid-Phase Synthesis." Acs Comb Sci, 15 (7), 2013, 331-334.
[107] Hassane, F. S.; Frisch, B.; Schuber, F., "Targeted liposomes: Convenient
coupling of ligands to preformed vesicles using "click chemistry"." Bioconjugate
Chem, 17 (3), 2006, 849-854.
[108] Kumar, A.; Erasquin, U. J.; Qin, G. T.; Li, K.; Cai, C. Z., ""Clickable'',
polymerized liposomes as a versatile and stable platform for rapid optimization of
their peripheral compositions." Chem Commun, 46 (31), 2010, 5746-5748.
[109] Smyth, T.; Petrova, K.; Payton, N. M.; Persaud, I.; Redzic, J. S.; Gruner,
M. W.; Smith-Jones, P.; Anchordoquy, T. J., "Surface Functionalization of
Exosomes Using Click Chemistry." Bioconjugate Chem, 25 (10), 2014, 1777-1784.
[110] Bianchini, E.; Pietrobon, L.; Ronchin, L.; Tortato, C.; Vavasori, A.,
"Trifluoroacetic acid promoted hydration of styrene catalyzed by sulfonic resins:
Comparison of the reactivity of styrene, n-hexene and cyclohexene." Appl Catal a-
Gen, 570, 2019, 130-138.